Entity

Time filter

Source Type


Yilmaz N.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Ozaksit G.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Keskin R.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Tapisiz O.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | And 5 more authors.
Cytokine | Year: 2012

Aim: The aim of this study is to investigate the effect of formoterol (β2 adrenergic receptor agonist) on peritoneal VEGF levels in rats with endometriosis. Materials and methods: Experimental endometriosis was constituted with implantation of endometrial tissue. The implants were examined by second laparatomy and rats were divided randomly into four groups. One cc saline was applied ip to the control (C) group (n= 8) daily, 22.5 μg/kg/day ip formoterol was applied to the second (F) group (n= 10) daily, 22.5 μg/kg/day ip formoterol and 10. mg/kg/day ip propranolol were applied to the third (FP) group (n= 10) daily, 45 μg/kg/day ip formoterol was applied to the fourth (FF) group (n= 9). Before treatment and after 30. days treatment period, peritoneal VEGF levels, the volumes and histopathological properties of the implants were evaluated. Results: There were significant differences in between the peritoneal VEGF levels before and after treatment in group 2(F) and group 4(FF) (p(a): 0.01, 0.01 respectively). But there were no significant changes in between the volumes of implants before and after treatment among the groups (p> 0.05). There were no significant differences among the groups in histopathological parameters (p> 0.05). Conclusion: Formoterol treatment was seen to have no effect on the volumes and histopathological structure of endometriotic implants in our study. On the other hand, based on the group 2(F) and 4's (FF) VEGF levels after the treatment, low dose or high dose formoterol may be effective with long term therapy. Formoterol may reduce the development of endometriosis. © 2012 Elsevier Ltd. Source


Guzel A.I.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Erkilinc S.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Ozer I.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Celik Y.,Dicle University | And 2 more authors.
Journal of Maternal-Fetal and Neonatal Medicine | Year: 2015

Objective: To evaluate the diagnostic value of screening laboratory tests in women who had recurrent pregnancy loss (RPL). Methods: A total of 252 women with RPL managed in our tertiary referral research and education hospital were included in the study. Risk factors recorded involved age, gravidity, parity, number of prior live births, number of pregnancy losses, and thrombophlia tests. The cases were divided into three different groups and each group was analyzed separately. Results: There was no statistically significant difference between the first and second groups in terms of clinical and laboratory parameters (p>0.05). In the third group, there was a statistically significant difference among cases in terms of parity, gravidity, number of pregnancy losses, serum AT III levels, APCR, and age of the women. According to the logistic regression model, odds ratios (95% CI) were 6.116 (3.797-9.852), 5.665 (2.657-12.079), 4.763 (3.099-7.321), 4.729 (3.080-7.260), 2.820 (1.836-4.333), and 1.911 (1.232-2.965), respectively. Conclusions: We do not recommend the screening of all women with RPL, but in women with high parity and those who had prior live birth pregnancies, increased AT III, and APCR may be diagnostic markers for subsequent pregnancy loss. © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted. Source


Inal H.A.,Konya Education and Research Hospital | Ozturk Inal Z.H.,Konya Education and Research Hospital | Tonguc E.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Var T.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital
Fertility and Sterility | Year: 2015

Objective To compare the effectiveness of vaginal misoprostol and dinoprostone for cervical ripening before diagnostic hysteroscopy in nulliparous women. Design Placebo-controlled, double blind, randomized trial. Setting Teaching and research hospital. Patient(s) Ninety women of reproductive age eligible for diagnostic hysteroscopy. Intervention(s) Randomly assignment to receive 400 μg of misoprostol (n = 30) or 10 mg of dinoprostone (n = 30) vaginally before diagnostic hysteroscopy, with a control group (n = 30) not receiving any cervical priming agent. Main Outcome Measure(s) Primary outcome: the number of women requiring cervical dilatation; secondary outcomes: cervical width before surgery, duration of dilatation time, ease of dilatation, complications during surgical procedure, and side effects of the drugs. Result(s) In the placebo group, 23 patients required cervical dilatation compared with 17 in the misoprostol group and 9 in the dinoprostone group. The mean (± standard deviation) cervical widths for the placebo, misoprostol, and dinoprostone groups were 4.23 ± 0.43 mm, 5.43 ± 0.5 mm, and 5.83 ± 0.64 mm, respectively. These widths were statistically significantly different. The duration of dilatation was also statistically significantly longer in the control group. Conclusion(s) Vaginally administered dinoprostone before diagnostic hysteroscopy is more effective than misoprostol for inducing cervical priming. Further studies are required to elucidate the most efficient option with the least side effects for cervical ripening. Clinical Trial Registration Number NCT01620814. © 2015 American Society for Reproductive Medicine. Source


Gultepe I.,Bezmialem Foundation University | Basaranolu M.,Bezmialem Foundation University | Suleymanolu Y.,Clinic of Diabetes | Baaranolu G.,Bezmialem Foundation University | Beyazit F.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital
Turkish Journal of Gastroenterology | Year: 2016

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) are common metabolic disorders. We aimed to evaluate the underlying mechanisms in the development of NAFLD and PCOS. Materials and Methods: Thirty female patients with NAFLD and without PCOS; 12 female patients with PCOS; and a control group with 17 healthy females were included. Pancreatic homeostatic model assessment-Beta cell function was measured by the homeostasis model assessment (HOMA)-B test. Results: The body mass index (BMI) of the NAFLD patients was higher than that of the PCOS patients (29.4±3.8 kg/m vs 25.6±5.2 kg/m, p<0.05). There was no significant difference between the PCOS patients and controls with respect to BMI. The fasting insulin levels of the NAFLD patients were higher than those of the PCOS patients (5.06 unit more than PCOS, p<0.05) and 12.8 unit more than controls (p<0.001). The HOMA scores of the NAFLD patients were more than those of the PCOS patients (1.41 unit more than PCOS, p<0.05) and 2.95 unit more than controls (p<0.001). The HOMA-B score was higher in the NAFLD patients than in the PCOS patients. There was no statistical difference among the groups for serum triglyceride (p>.05) and cholesterol (p>.05). Conclusion: This study showed that rather than pancreatic beta-cell hyperfunction, insulin resistance plays a central role in the development of ovarian abnormalities. © Copyright 2016 by The Turkish Society of Gastroenterology. Source


Inal H.A.,Konya Education and Research Hospital | Yilmaz N.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Gorkem U.,Hitit University | Oruc A.S.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital | Timur H.,Dr Zekai Tahir Burak Womens Health Research And Education Hospital
Journal of Endocrinological Investigation | Year: 2016

Purpose: This study aimed at evaluating the effects of polycystic ovary syndrome (PCOS) and body mass index (BMI) on follicular fluid (FF) adiponectin and ghrelin levels, and on in vitro fertilization outcomes in patients who underwent controlled ovarian hyperstimulation. Methods: This prospective cross-sectional study was performed with a total of 120 primary infertile women [group 1; non-PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30) and group 2; PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30)]. On the day of oocyte pickup, FF samples were collected. Results: The FF adiponectin levels were lower in the lean PCOS group than the lean non-PCOS group (p = 0.001), and these levels were lower in the overweight non-PCOS group compared to lean non-PCOS group (0.001). However, there was no difference in the FF ghrelin levels between the groups. Additionally, we could not find a relationship between clinical pregnancy and adiponectin and ghrelin levels. Conclusion: The FF adiponectin and ghrelin levels have no effects on clinical pregnancy in PCOS. Therefore, further studies are needed to elucidate this issue. © 2015 Italian Society of Endocrinology (SIE). Source

Discover hidden collaborations